Patents by Inventor Jurgen KLAR
Jurgen KLAR has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230065629Abstract: The present invention covers substituted 6-(1H-pyrazol-1-yl)pyrimidin-4-amine compounds of general formula (I) as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular and renal diseases, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: November 4, 2021Publication date: March 2, 2023Applicants: Bayer Aktiengesellschaft, Bayer Pharma AktiengesellschaftInventors: Anja GIESE, Jürgen KLAR, Alexander Helmut Michael EHRMANN, Jens WILLWACHER, David ENGEL, Andre Philippe DIESKAU, Antje KAHNERT, Alexey GROMOV, Carsten SCHMECK, Niels LINDNER, Thomas MÜLLER, Anna Lena ANDREEVSKI, Jan DREHER, Karl COLLINS
-
Publication number: 20230053411Abstract: The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: September 9, 2021Publication date: February 23, 2023Applicant: Bayer AktiengesellschaftInventors: Adam James DAVENPORT, Nico BRÄUER, Oliver Martin FISCHER, Andrea ROTGERI, Antje ROTTMANN, Ioana NEAGOE, Jens NAGEL, Anne-Marie GODINHO-COELHO, Jürgen KLAR
-
Publication number: 20230027985Abstract: The application relates to substituted hydantoinamides of formula (I) as ADAMTS7 antagonists, to processes for their preparation, their use alone or in combination for the treatment or prophylaxis of diseases, in particular of cardiovascular diseases, including atherosclerosis, coronary artery disease (CAD), peripheral vascular disease (PAD), arterial occlusive disease or restenosis after angioplasty. R1 is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, 5- to 6-membered heteroaryl or phenyl; R2 is hydrogen or alkyl; A is 5-membered heteroaryl; Z is 6- to 10-membered aryl or 5- to 10-membered heteroaryl; all groups being optionally substituted.Type: ApplicationFiled: November 12, 2020Publication date: January 26, 2023Applicants: Bayer Aktiengesellschaft, The Broad Institute, Inc.Inventors: Daniel MEIBOM, Yolanda CANCHO GRANDE, Pierre WASNAIRE, Sarah Anna Liesa JOHANNES, Niels LINDNER, Kristin BEYER, Till FREUDENBERGER, Damian BROCKSCHNIEDER, Ilka MATHAR, Jürgen KLAR, Dmitry ZUBOV, Dzianis MENSHYKAU, Tanja KRAINZ, Eric STEFAN, Bryan MACDONALD, Yi XING, Nadine ELOWE, Guzman SANCHEZ
-
Patent number: 11208400Abstract: The present invention covers substituted 6-(1H-pyrazol-1-yl)pyrimidin-4-amine compounds of general formula (I) as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular and renal diseases, as a sole agent or in combination with other active ingredients.Type: GrantFiled: October 9, 2017Date of Patent: December 28, 2021Assignees: Bayer Aktiengesellschaft, Bayer Pharma AktiengesellschaftInventors: Anja Giese, Jürgen Klar, Alexander Helmut Michael Ehrmann, Jens Willwacher, David Engel, Andre Philippe Dieskau, Antje Kahnert, Alexey Gromov, Carsten Schmeck, Niels Lindner, Thomas Müller, Anna Lena Andreevski, Jan Dreher, Karl Collins
-
Patent number: 11142523Abstract: The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.Type: GrantFiled: October 1, 2019Date of Patent: October 12, 2021Assignee: Bayer AktiengesellschaftInventors: Adam James Davenport, Nico Bräuer, Oliver Martin Fischer, Andrea Rotgeri, Antje Rottmann, Ioana Neagoe, Jens Nagel, Anne-Marie Godinho-Coelho, Jürgen Klar
-
Publication number: 20200131169Abstract: The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: October 1, 2019Publication date: April 30, 2020Applicant: Bayer AktiengesellschaftInventors: Adam James DAVENPORT, Nico BRÄUER, Oliver Martin FISCHER, Andrea ROTGERI, Antje ROTTMANN, Ioana NEAGOE, Jens NAGEL, Anne-Marie GODINHO-COELHO, Jürgen KLAR
-
Publication number: 20200055842Abstract: The present invention covers substituted 6-(1H-pyrazol-1-yl)pyrimidin-4-amine compounds of general formula (I) as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular and renal diseases, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: October 9, 2017Publication date: February 20, 2020Applicants: Bayer Aktiengesellschaft, Bayer Pharma AktiengesellschaftInventors: Anja GIESE, Jürgen KLAR, Alexander Helmut Michael EHRMANN, Jens WILLWACHER, David ENGEL, Andre Philippe DIESKAU, Antje KAHNERT, Alexey GROMOV, Carsten SCHMECK, Niels LINDNER, Thomas MÜLLER, Anna Lena ANDREEVSKI, Jan DREHER, Karl COLLINS
-
Patent number: 10472354Abstract: The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.Type: GrantFiled: November 15, 2018Date of Patent: November 12, 2019Assignee: Bayer AktiengesellschaftInventors: Adam James Davenport, Nico Bräuer, Oliver Martin Fischer, Andrea Rotgeri, Antje Rottmann, Ioana Neagoe, Jens Nagel, Anne-Marie Godinho-Coelho, Jürgen Klar
-
Publication number: 20190185466Abstract: The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: November 15, 2018Publication date: June 20, 2019Applicant: Bayer AktiengesellschaftInventors: Adam James DAVENPORT, Nico BRÄUER, Oliver Martin FISCHER, Andrea ROTGERI, Antje ROTTMANN, Ioana NEAGOE, Jens NAGEL, Anne-Marie GODINHO-COELHO, Jürgen KLAR
-
Patent number: 10202369Abstract: The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.Type: GrantFiled: November 21, 2017Date of Patent: February 12, 2019Assignee: Bayer AktiengesellschaftInventors: Adam James Davenport, Nico Bräuer, Oliver Martin Fischer, Andrea Rotgeri, Antje Rottmann, Ioana Neagoe, Jens Nagel, Anne-Marie Godinho-Coelho, Jürgen Klar
-
Patent number: 10183932Abstract: The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.Type: GrantFiled: October 17, 2017Date of Patent: January 22, 2019Assignee: Bayer Pharma AktiengesellschaftInventors: Susanne Röhrig, Alexander Hillisch, Julia Strassburger, Stefan Heitmeier, Martina Victoria Schmidt, Karl-Heinz Schlemmer, Adrian Tersteegen, Anja Buchmüller, Christoph Gerdes, Martina Schäfer, Tom Kinzel, Henrik Teller, Hartmut Schirok, Jürgen Klar, Eloisa Jimenez Nunez
-
Patent number: 10183937Abstract: The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.Type: GrantFiled: November 21, 2017Date of Patent: January 22, 2019Assignee: Bayer AktiengesellschaftInventors: Adam James Davenport, Nico Bräuer, Oliver Martin Fischer, Andrea Rotgeri, Antje Rottmann, Ioana Neagoe, Jens Nagel, Anne-Marie Godinho-Coelho, Jürgen Klar
-
Patent number: 10174016Abstract: The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.Type: GrantFiled: December 7, 2015Date of Patent: January 8, 2019Assignee: BEYER AKTIENGESELLSCHAFTInventors: Adam James Davenport, Nico Bräuer, Oliver Martin Fischer, Andrea Rotgeri, Antje Rottmann, Ioana Neagoe, Jens Nagel, Anne-Marie Godinho-Coelho, Jürgen Klar
-
Patent number: 10077265Abstract: The invention relates to substituted oxopyridine derivatives and to processes for preparation thereof, and also to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.Type: GrantFiled: September 22, 2015Date of Patent: September 18, 2018Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Susanne Röhrig, Alexander Hillisch, Julia Straβburger, Stefan Heitmeier, Martina Victoria Schmidt, Karl-Heinz Schlemmer, Adrian Tersteegen, Anja Buchmüller, Christoph Gerdes, Martina Schäfer, Henrik Teller, Eloisa Jiménez Núnez, Hartmut Schirok, Jürgen Klar, Mario Lobell
-
Patent number: 10047096Abstract: The present application relates to novel (3-hydroxyphenyl)amino-substituted pyrido[2,3-b][1,5]benzodiazepin-5-one derivatives, to processes for preparation thereof, to the use thereof alone or in combination for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially of angiogenic disorders and hyperproliferative disorders in which neovascularization plays a role, for example ophthalmological disorders and cancers and tumours. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.Type: GrantFiled: November 23, 2015Date of Patent: August 14, 2018Assignee: Bayer Pharma AktiengesellschaftInventors: Andreas Schall, Jürgen Klar, Mario Lobell, Hartmut Schirok, Joachim Telser, Steffen Müller, Dirk Brohm, Hans Briem, Hannah Jörißen, Joerg Keldenich, Michael Böttger, Georges Von Degenfeld, Thomas Schlange, Ulf Bömer, Niels Lindner, Hanna Eilken, Dmitrij Hristodorov, Pierre Wasnaire, Kersten Matthias Gericke, Lars Bärfacker
-
Publication number: 20180086742Abstract: The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.Type: ApplicationFiled: October 17, 2017Publication date: March 29, 2018Inventors: Susanne RÖHRIG, Alexander HILLISCH, Julia STRASSBURGER, Stefan HEITMEIER, Martina Victoria SCHMIDT, Karl-Heinz SCHLEMMER, Adrian TERSTEEGEN, Anja BUCHMÜLLER, Christoph GERDES, Martina SCHÄFER, Tom KINZEL, Henrik TELLER, Harmut SCHIROK, Jürgen KLAR, Eloisa Jimenez NUNEZ
-
Patent number: 9822102Abstract: The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.Type: GrantFiled: September 4, 2016Date of Patent: November 21, 2017Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Susanne Röhrig, Alexander Hillisch, Julia Strassburger, Stefan Heitmeier, Martina Victoria Schmidt, Karl-Heinz Schlemmer, Adrian Tersteegen, Anja Buchmüller, Christoph Gerdes, Martina Schäfer, Tom Kinzel, Henrik Teller, Hartmut Schirok, Jürgen Klar, Eloisa Jimenez Nunez
-
Publication number: 20170283412Abstract: The invention relates to substituted oxopyridine derivatives and to processes for preparation thereof, and also to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.Type: ApplicationFiled: September 22, 2015Publication date: October 5, 2017Inventors: Susanne RÖHRIG, Alexander HILLISCH, Julia STRAßBURGER, Stefan HEITMEIER, Martina Victoria SCHMIDT, Karl-Heinz SCHLEMMER, Adrian TERSTEEGEN, Anja BUCHMÜLLER, Christoph GERDES, Martina SCHÄFER, Henrik TELLER, Eloisa JIMÉNEZ NÚNEZ, Hartmut SCHIROK, Jürgen KLAR, Mario LOBELL
-
Patent number: 9765070Abstract: The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.Type: GrantFiled: October 28, 2014Date of Patent: September 19, 2017Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Susanne Röhrig, Alexander Hillisch, Julia Strassburger, Stefan Heitmeier, Martina Victoria Schmidt, Karl-Heinz Schlemmer, Adrian Tersteegen, Anja Buchmüller, Christoph Gerdes, Martina Schäfer, Henrik Teller, Eloisa Jimenez Nunez, Hartmut Schirok, Jürgen Klar
-
Publication number: 20170253602Abstract: The present application relates to novel (3-hydroxyphenyl)amino-substituted pyrido[2,3-b][1,5]benzodiazepin-5-one derivatives, to processes for preparation thereof, to the use thereof alone or in combination for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially of angiogenic disorders and hyperproliferative disorders in which neovascularization plays a role, for example ophthalmological disorders and cancers and tumours. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.Type: ApplicationFiled: November 23, 2015Publication date: September 7, 2017Applicant: Bayer Pharma AktiengesellschaftInventors: Andreas SCHALL, Jürgen KLAR, Mario LOBELL, Hartmut SCHIROK, Joachim TELSER, Steffen MÜLLER, Dirk BROHM, Hans BRIEM, Hannah JÖRIßEN, Joerg KELDENICH (deceased), Michael BÖTTGER, Georges DEGENFELD VON, Thomas SCHLANGE, Ulf BÖMER, Niels LINDNER, Hanna EILKEN, Dmitrij HRISTODOROV, Pierre WASNAIRE, Kersten Matthias GERICKE, Lars BÄRFACKER